Investments
38Portfolio Exits
13Funds
10Partners & Customers
2Service Providers
1About NovaQuest Capital Management
NovaQuest Capital Management (NovaQuest) manages private equity and other investments in the global biopharmaceutical sector, where its principal focus is investing in late-stage clinical assets and commercial phase biopharmaceutical products. NovaQuest contracts with global biopharmaceutical corporations to invest side-by-side in strategic development and commercialization programs.
NovaQuest Capital Management Headquarter Location
4208 Six Forks Road Suite 920
Raleigh, North Carolina, 27609,
United States
919-459-8620
NovaQuest Capital Management Web Traffic
NovaQuest Capital Management Rank
Latest NovaQuest Capital Management News
May 4, 2022
The agreement provides for an upfront $100M cash payment and an additional $160M cash payment upon FDA approval of vonoprazan for treatment of EE. Sagard Healthcare Partners, NovaQuest Capital Management and Hercules Capital have committed to providing $260M, including the first $100M payment and commitments for an additional $160M upon EE approval. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
NovaQuest Capital Management Investments
38 Investments
NovaQuest Capital Management has made 38 investments. Their latest investment was in CovenantAH as part of their Secondary Market on November 11, 2021.
NovaQuest Capital Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/30/2021 | Secondary Market | CovenantAH | Yes | 2 | ||
6/8/2021 | Revenue Finance | Dermavant | $160M | Yes | 4 | |
5/3/2021 | Series A | Aceragen | $35M | Yes | 4 | |
2/23/2021 | Private Equity | |||||
10/19/2020 | Private Equity |
Date | 11/30/2021 | 6/8/2021 | 5/3/2021 | 2/23/2021 | 10/19/2020 |
|---|---|---|---|---|---|
Round | Secondary Market | Revenue Finance | Series A | Private Equity | Private Equity |
Company | CovenantAH | Dermavant | Aceragen | ||
Amount | $160M | $35M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 4 | 4 |
NovaQuest Capital Management Portfolio Exits
13 Portfolio Exits
NovaQuest Capital Management has 13 portfolio exits. Their latest portfolio exit was Roivant Sciences on October 01, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
10/1/2021 | Reverse Merger | 4 | |||
1/4/2021 | Acquired | 18 | |||
8/5/2020 | Merger | 3 | |||
Date | 10/1/2021 | 1/4/2021 | 8/5/2020 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | Acquired | Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 4 | 18 | 3 |
NovaQuest Capital Management Acquisitions
6 Acquisitions
NovaQuest Capital Management acquired 6 companies. Their latest acquisition was CoreRX on January 19, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
1/19/2021 | Debt | $18.5M | Acq - Fin | 10 | ||
11/2/2018 | ||||||
5/14/2018 | Debt | |||||
3/26/2018 | Debt | |||||
1/3/2018 | Series E+ |
Date | 1/19/2021 | 11/2/2018 | 5/14/2018 | 3/26/2018 | 1/3/2018 |
|---|---|---|---|---|---|
Investment Stage | Debt | Debt | Debt | Series E+ | |
Companies | |||||
Valuation | |||||
Total Funding | $18.5M | ||||
Note | Acq - Fin | ||||
Sources | 10 |
NovaQuest Capital Management Fund History
10 Fund Histories
NovaQuest Capital Management has 10 funds, including NovaQuest Private Equity Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
5/12/2022 | NovaQuest Private Equity Fund II | $500M | 1 | ||
11/5/2019 | NovaQuest Private Equity Fund I | Diversified Private Equity | Closed | $275M | 6 |
6/24/2019 | NovaQuest Pharma Opportunities Fund V | Diversified Private Equity | Open | $892.75M | 5 |
3/8/2019 | NQ PE Project Constellation | ||||
6/29/2018 | NQ PE Project Kit LP |
Closing Date | 5/12/2022 | 11/5/2019 | 6/24/2019 | 3/8/2019 | 6/29/2018 |
|---|---|---|---|---|---|
Fund | NovaQuest Private Equity Fund II | NovaQuest Private Equity Fund I | NovaQuest Pharma Opportunities Fund V | NQ PE Project Constellation | NQ PE Project Kit LP |
Fund Type | Diversified Private Equity | Diversified Private Equity | |||
Status | Closed | Open | |||
Amount | $500M | $275M | $892.75M | ||
Sources | 1 | 6 | 5 |
NovaQuest Capital Management Partners & Customers
2 Partners and customers
NovaQuest Capital Management has 2 strategic partners and customers. NovaQuest Capital Management recently partnered with Grunenthal Group on March 3, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
3/29/2022 | Partner | Germany | Aachen , Germany , and Raleigh , North Carolina - Grünenthal and NovaQuest Capital Management announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal 's asset resiniferatoxin . | 4 | |
5/14/2018 | Partner |
Date | 3/29/2022 | 5/14/2018 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | Germany | |
News Snippet | Aachen , Germany , and Raleigh , North Carolina - Grünenthal and NovaQuest Capital Management announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal 's asset resiniferatoxin . | |
Sources | 4 |
NovaQuest Capital Management Service Providers
1 Service Provider
NovaQuest Capital Management has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Private Equity, and Acq - Fin | Counsel | General Counsel |
Service Provider | |
|---|---|
Associated Rounds | Private Equity, and Acq - Fin |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
NovaQuest Capital Management Team
4 Team Members
NovaQuest Capital Management has 4 team members, including current Chief Financial Officer, Robert Hester.
Name | Work History | Title | Status |
|---|---|---|---|
Robert Hester | Chief Financial Officer | Current | |
Ronald Wooten | Managing Partner | Current | |
John Bradley | Senior Partner | Current | |
Maulik Mehta | Senior Director | Former |
Name | Robert Hester | Ronald Wooten | John Bradley | Maulik Mehta |
|---|---|---|---|---|
Work History | ||||
Title | Chief Financial Officer | Managing Partner | Senior Partner | Senior Director |
Status | Current | Current | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.